Related references
Note: Only part of the references are listed.PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
Xuejiao Song et al.
SCIENTIFIC REPORTS (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway
Alessandra Leone et al.
FREE RADICAL BIOLOGY AND MEDICINE (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy
Jeenah Park et al.
EPIGENOMICS (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia
Shaliny Ramachandran et al.
GENES (2015)
OX40 agonists anc combination immunotherapy: putting the pedal to the metal
Stefanie N. Linch et al.
FRONTIERS IN ONCOLOGY (2015)
DNA Methyltransferase Inhibitor Zebularine Induces Human Cholangiocarcinoma Cell Death through Alteration of DNA Methylation Status
Kazuaki Nakamura et al.
PLOS ONE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt et al.
BLOOD (2014)
Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
Lei Lu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
H. Yang et al.
LEUKEMIA (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression
Y. Oki et al.
BLOOD CANCER JOURNAL (2014)
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Huili Li et al.
ONCOTARGET (2014)
HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen et al.
ONCOTARGET (2014)
Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
Deborah J. L. Wong et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The anticancer effects of HDAC inhibitors require the immune system
Alison C. West et al.
ONCOIMMUNOLOGY (2014)
OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Brendan D. Curti et al.
CANCER RESEARCH (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Manipulating the PD-1 pathway to improve immunity
Alice O. Kamphorst et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Decitabine: A Review of its Use in Older Patients with Acute Myeloid Leukaemia
Monique P. Curran
DRUGS & AGING (2013)
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
Benedetta Costantini et al.
HAEMATOLOGICA (2013)
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sibaji Sarkar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy
Margaret K. Callahan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors
Feng Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Byram W. Bridle et al.
MOLECULAR THERAPY (2013)
Chromatin proteins and modifications as drug targets
Kristian Helin et al.
NATURE (2013)
Efficacy of Histone Deacetylase and Estrogen Receptor Inhibition in Breast Cancer Cells Due to Concerted down Regulation of Akt
Scott Thomas et al.
PLOS ONE (2013)
Demethylation and re-expression of epigenetically silenced tumor suppressor genes: sensitization of cancer cells by combination therapy
Sibaji Sarkar et al.
EPIGENOMICS (2013)
Alterations of immune response of non-small cell lung cancer with Azacytidine
John Wrangle et al.
ONCOTARGET (2013)
Histone/protein deacetylases and T-cell immune responses
Tatiana Akimova et al.
BLOOD (2012)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Trials with 'epigenetic' drugs: An update
Angela Nebbioso et al.
MOLECULAR ONCOLOGY (2012)
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen et al.
PLOS ONE (2012)
T Cell Signaling Targets for Enhancing Regulatory or Effector Function
Fan Pan et al.
SCIENCE SIGNALING (2012)
Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms
Ulf H. Beier et al.
SCIENCE SIGNALING (2012)
被撤回的出版物: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies (Retracted article. See vol. 134, pg. 658, 2019)
Holbrook E. Kohrt et al.
BLOOD (2011)
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status
J. Simova et al.
BRITISH JOURNAL OF CANCER (2011)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
Scott R. Daigle et al.
CANCER CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Strategies to counteract MHC-I defects in tumors
Margit H. Lampen et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Epigenetic-Based Therapies in Cancer Progress to Date
Sang-Hyun Song et al.
DRUGS (2011)
Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells
Scott K. Pruitt et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
K. Ted Thurn et al.
FUTURE ONCOLOGY (2011)
Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells
Ben Youngblood et al.
IMMUNITY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
Ailsa J. Christiansen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Role of Gene Methylation in Antitumor Immune Response: Implication for Tumor Progression
Alfonso Serrano et al.
Cancers (2011)
Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
Paul A. Marks
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
E. Di Gennaro et al.
BRITISH JOURNAL OF CANCER (2010)
Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
Martin Sauvageau et al.
CELL STEM CELL (2010)
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Jun Mitsui et al.
CLINICAL CANCER RESEARCH (2010)
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+Tregs
Tatiana Akimova et al.
CLINICAL IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
Lisa A. Cowan et al.
EPIGENOMICS (2010)
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
K. S. Peggs et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Tsvetelina Pentcheva-Hoang et al.
IMMUNOLOGICAL REVIEWS (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mutator pathways unleashed by epigenetic silencing in human cancer
Filipe V. Jacinto et al.
MUTAGENESIS (2007)
Tumor-associated macrophages press the angiogenic switch in breast cancer
Elaine Y. Lin et al.
CANCER RESEARCH (2007)
Histone deacetylase inhibitors: A new wave of molecular targeted anticancer agents
Alfredo Budillon et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L
Michael S. Kareta et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Epigenetics as a mechanism driving polygenic clinical drug resistance
RM Glasspool et al.
BRITISH JOURNAL OF CANCER (2006)
DNA methyltransferases control telomere length and telomere recombination in mammalian cells
S Gonzalo et al.
NATURE CELL BIOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase
A Budillon et al.
CURRENT DRUG TARGETS (2005)
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
MS Kim et al.
NATURE MEDICINE (2001)
The DNA methyltransferases of mammals
TH Bestor
HUMAN MOLECULAR GENETICS (2000)
Share Paper
